Copyright
©The Author(s) 2023.
World J Gastroenterol. Nov 7, 2023; 29(41): 5683-5698
Published online Nov 7, 2023. doi: 10.3748/wjg.v29.i41.5683
Published online Nov 7, 2023. doi: 10.3748/wjg.v29.i41.5683
Figure 1 Clinical and pathological profile of CBC2T-2.
A and B: Contrast-enhanced computed tomography of the abdomen showing a high-grade occupying lesion of the common bile duct with high level obstruction of the common bile duct (orange arrows); C: Specimen of postoperative carcinosarcoma of the extrahepatic bile duct with thickened duct wall and polyp-like protrusion into the lumen; D and E: Hematoxylin and eosin and immunohistochemistry staining of primary tumor tissue. Scale bars, 200 μm; F: Immunohistochemistry staining of primary tumor tissue. Antibodies against Vimentin, Scale bars, 200 μm; G: Clinicopathological characteristics of patients. AFP: Alpha-fetoprotein; CEA: Carcinoembryonic antigen; CA199: Carbohydrate antigen199.
- Citation: Jiang NZ, Bai MZ, Huang CF, Ma ZL, Zhong RY, Fu WK, Gao L, Tian L, Mi NN, Ma HD, Lu YW, Zhang ZA, Zhao JY, Yu HY, Zhang BP, Zhang XZ, Ren YX, Zhang C, Zhang Y, Yue P, Lin YY, Meng WB. First report on establishment and characterization of the extrahepatic cholangiocarcinoma sarcoma cell line CBC2T-2. World J Gastroenterol 2023; 29(41): 5683-5698
- URL: https://www.wjgnet.com/1007-9327/full/v29/i41/5683.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i41.5683